Physician profile
Olivia Mae Eckstein
NPI 1902357759
$6,000.21
in general payments reported to CMS, 2019-2025
22 companies · $1,345 in 2025
The $1,345 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $510 · 2022: $856 · 2023: $1,261 · 2024: $2,028 · 2025: $1,345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,272 · Education: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,271.97 |
| Education | $362.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,176.02 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $1,124.96 | 2021-2025 | |
| Janssen Biotech, INC. | $1,117.46 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $622.37 | 2022-2025 | Winlevi, Absorica Ld, Ilumya |
| E.R. Squibb & Sons, L.L.C. | $492.27 | 2022-2025 | Sotyktu |
| Amgen INC. | $246.43 | 2022-2025 | Otezla, Otezla, Repatha |
| Regeneron Healthcare Solutions, INC. | $244.93 | 2022-2025 | Dupixent, Libtayo |
| Ucb, INC. | $185.91 | 2021-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $124.17 | 2021-2025 | Nemluvio |
| Glaxosmithkline, LLC. | $109.36 | 2021 | |
| Pfizer INC. | $107.70 | 2022-2023 | |
| Dermavant Sciences, INC. | $96.10 | 2023 | Vtama |
| Genzyme Corporation | $95.34 | 2024-2025 | |
| Leo Pharma INC. | $56.08 | 2024-2025 | Adbry |
| Lilly USA, LLC | $55.91 | 2022-2025 | Ebglyss, Taltz |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $32.99 | 2023-2024 | Opzelura |
| Verrica Pharmaceuticals INC. | $21.36 | 2025 | Ycanth |
| Celgene Corporation | $20.46 | 2024 | Sotyktu |
| Janssen Scientific Affairs, LLC | $17.85 | 2022 | |
| Arcutis Biotherapeutics, INC. | $17.63 | 2023 | |
| Integra Lifesciences Corporation | $17.50 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.41 | 2023 | Spevigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Eckstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.